Hemostemix (HEM) Stock Price Down 12.5%
Hemostemix Inc (CVE:HEM) fell 12.5% during mid-day trading on Tuesday . The company traded as low as C$0.11 and last traded at C$0.11. 200,000 shares changed hands during trading, a decline of 25% from the average session volume of 266,036 shares. The stock had previously closed at C$0.12.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/12/06/hemostemix-hem-stock-price-down-12-5.html.
Hemostemix Company Profile (CVE:HEM)
Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.
Further Reading: What is a Swap?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.